Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus pembrolizumab versus pembrolizumab in metastatic dMMR/MSI-H colorectal cancer
ChiCTR2100051400Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing Fruquintinib combined with anti-PD-1 group with Anti-PD-1 group (2 arms). Primary endpoints: Adverse reaction grade and Quality of life score. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
fruquintinibpembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051400.